Abstract
Identifying blood biomarkers may be of particular value in neurologic disorders such as stroke because of the difficulty in directly studying the brain and its blood vessels. Markers of brain injury, inflammation, excitotoxicity, and oxidative damage have been evaluated for their value in stroke diagnosis, treatment, and management, but none has proved to be sensitive or specific enough for routine clinical use. However, new cellular and molecular profiling approaches using the peripheral blood offer the potential for identifying panels of genes and proteins by increasing specificity while maintaining sensitivity. Furthermore, the first biomarker for predicting stroke risk associated with atherosclerosis (lipoprotein-associated phospholipase A2) was recently approved by the United States Food and Drug Administration. The ultimate aim for stroke biomarkers is to develop rapid, easy to use, widely available, and inexpensive diagnostic tests that can be used in the clinic and in clinical trials.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Hill MD: Diagnostic biomarkers for stroke: a stroke neurologist’s perspective. Clin Chem 2005, 51:2001–2002.
Goldstein LB, Simel DL: Is this patient having a stroke? JAMA 2005, 293:2391–2402.
Norris JW, Hachinski VC: Misdiagnosis of stroke. Lancet 1982, 1:328–331.
Hand PJ, Kwan J, Lindley RI, et al.: Distinguishing between stroke and mimic at the bedside. The Brain Attack Study. Stroke 2006, 37:769–775.
Kidwell CS, Chalela JA, Saver JL, et al.: Comparison of MRI and CT for detection of acute intracerebral hemorrhage. JAMA 2004, 292:1823–1830.
Baird AE, Dambrosia J, Janket S, et al.: A three-item scale for the early prediction of stroke recovery. Lancet 2001, 357:2095–2099.
Mayer SA, Brun NC, Begtrup K, et al.: Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005, 352:777–785.
Lees KR, Zivin JA, Ashwood T, et al.: NXY-059 for acute ischemic stroke. N Engl J Med 2006, 354:588–600.
Hsieh KM, Blumenthal HT: Serum lactic dehydrogenase levels in various disease states. Proc Soc Exp Biol Med 1956, 91:626–630.
Biomarkers Definitions Working Group: Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89–95.
Griffiths HR, Moller L, Bartosz G, et al.: Biomarkers. Mol Aspects Med 2002, 23:101–208.
Echt DS, Liebson PR, Mitchell LB, et al.: Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991, 324:781–788.
Mitka M: Biomarkers for coronary heart disease: predictive value or background noise? JAMA 2004, 292:2824–2845.
Brotman DJ, Walker E, Lauer MS, O’Brien RG: In search of fewer independent risk factors. Arch Intern Med 2005, 165:138–145.
Greenland P, O’Malley PG: When is a new prediction marker useful? A consideration of lipoprotein-associated phospholipase A2 and C-reactive protein for stroke risk. Arch Intern Med 2005, 165:2454–2456.
Margolis KL, Manson JE, Greenland P, et al.: Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: the Women’s Health Initiative Observational Study. Arch Intern Med 2005, 165:500–508.
Elkind MS, Sciacca RR, Boden-Albala B, et al.: Relative elevation in baseline leukocyte count predicts first cerebral infarction. Neurology 2005, 64:2121–2125.
Dubo H, Park DC, Pennington RJ, et al.: Serum-creatinekinase in cases of stroke, head injury, and meningitis. Lancet 1967, 2:743–748.
Kaste M, Somer H, Kontinnen A: Brain-type creatine kinase iso-enzyme. Arch Neurol 1977, 34:142–144.
Bell RD, Rosenberg RN, Ting R, et al.: Creatine kinase BB isoenzyme levels by radio-immuno-assay in patients with neurological disease. Ann Neurol 1978, 3:52–59.
Norris JW, Hachinski VC, Myers MG, et al.: Serum cardiac enzymes in stroke. Stroke 1979, 10:548–553.
Persson L, Hardemark HG, Gustafsson J, et al.: S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system. Stroke 1987, 18:911–918.
Fassbender K, Schmidt R, Schreiner A, et al.: Leakage of brain-originated proteins in peripheral blood: temporal profile and diagnostic value in early ischemic stroke. J Neurol Sci 1997, 148:101–105.
Sharp FR, Lu A, Tang Y, Millhorn DE: Multiple molecular penumbras after focal cerebral ischemia. J Cereb Blood Flow Metab 2000, 20:1011–1032.
Onteniente B, Rasika S, Benchoua A, Guegan C: Molecular pathways in cerebral ischemia: cues to novel therapeutic strategies. Mol Neurobiol 2003, 27:33–72.
Weinstein PR, Hong S, Sharp FR: Molecular identification of the ischemic penumbra. Stroke 2004, 35(Suppl 1):2666–2670.
Castillo J, Rodriguez I: Biochemical changes and inflammatory response as markers for brain ischaemia: molecular markers of diagnostic utility and prognosis in human clinical practice. Cerebrovasc Dis 2004, 17(Suppl):17–18.
Cherubini A, Ruggiero C, Polidori MC, Mecocci P: Potential markers of oxidative stress in stroke. Free Radic Biol Med 2005, 39:841–852.
Vila N, Castillo J, Davalos A, Chamorro A: Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke 2000, 31:2325–2329.
Castellanos M, Leira R, Serena J, et al.: Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke 2003, 34:40–46.
Ransohoff DF: Developing molecular markers for cancer. Science 2003, 299:1679–1680.
Calvano SE, Xiao W, Richards DR, et al.: A network-based analysis of systemic inflammation in humans. Nature 2005, 437:1032–1037.
Sebastiani P, Ramoni MF, Nolan V, et al: Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia. Nat Genet 2005, 37:435–440.
Moore DF, Li H, Jeffries N, et al.: Using peripheral blood mononuclear cells to determine a gene expression profile of acute ischemic stroke: a pilot investigation. Circulation 2005, 111:212–221.
Tang Y, Xu H, Du X, et al.: Gene expression in blood changes rapidly in neutrophils and monocytes after ischemic stroke in humans: a microarray study. J Cereb Blood Flow Metab 2006, 26:1089–1102.
Lynch JR, Blessing R, White WD, et al.: Novel diagnostic test for acute stroke. Stroke 2004, 35:57–63.
Reynolds MA, Kirchick HJ, Dahlen JR, et al.: Early biomarkers of stroke. Clin Chem 2003, 49:1733–1739.
Allard L, Burkhard PR, Lescuyer P, et al.: PARK7 and nucleoside diphosphate kinase A as plasma markers for the early diagnosis of stroke. Clin Chem 2005, 51:2043–2051.
Allard L, Lescuyer P, Burgess J, et al.: ApoC-I and ApoC-III as potential plasmatic markers to distinguish between ischemic and hemorrhagic stroke. Proteomics 2004, 4:2242–2251.
Simak J, Gelderman M, Yu H, et al.: Elevated circulating endothelial microparticles in acute stroke patients: a correlation with brain lesion volume and clinical outcome. Blood 2004, 104:954.
Nadar SK, Lip GY, Lee KW, Blann AD: Circulating endothelial cells in acute ischaemic stroke. Thromb Haemost 2005, 94:707–712.
Nadareishvili ZG, Li H, Wright V, et al.: Elevated proinflammatory CD4+CD28-lymphocytes and stroke recurrence and death. Neurology 2004, 63:1446–1451.
Garlichs CD, Kozina S, Fateh-Moghadam S, et al.: Upregulation of CD40-CD40 ligand (CD154) in patients with acute cerebral ischemia. Stroke 2003, 34:1412–1418.
Paczkowska E, Larysz B, Rzeuski R, et al.: Human hematopoietic stem/progenitor-enriched CD34(+) cells are mobilized into peripheral blood during stress related to ischemic stroke or acute myocardial infarction. Eur J Haematol 2005, 75:461–467.
Elkind M, Coates A, Tai W, Sacco RL: Lipoprotein-associated phospholipase A2 and C-reactive protein as predictors of stroke recurrence and death: The Northern Manhattan Stroke Study. Stroke 2006, 37:625–626.
Libby P: Inflammation in atherosclerosis. Nature 2002, 420:868–874.
Ballantyne CM, Hoogeveen RC, Bang H, et al.: Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med 2005, 165:2479–2484.
Di Napoli M, Schwaninger M, Cappelli R, et al.: Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. Stroke 2005, 36:1316–1329.
Smith SC Jr, Anderson JL, Cannon RO 3rd, et al.: CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the clinical practice discussion group. Circulation 2004, 110:e550–e553.
Ridker PM; JUPITER Study Group: Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 2003, 108:2292–2297.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Baird, A.E. Blood biologic markers of stroke: Improved management, reduced cost?. Curr Cardio Risk Rep 1, 80–88 (2007). https://doi.org/10.1007/s12170-007-0013-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12170-007-0013-9